Søgeord

Søgning på udtrykket 'ivermectin' giver 23 resultater

Nyt fra tidsskrifterne [20] Aktuelle smitsomme sygdomme [3]

Nyt fra tidsskrifterne [20]

Der er mere end 20 resultater, måske du vil se flere resultater her?
International Journal of Infectious Diseases
25.07.2021
Dear Sir
BMC Infectious Diseases
2.07.2021
…ntific community has been investigating re-purposed treatments to prevent disease progression in coronavirus disease (COVID-19) patients. Objective To determine whether ivermectin treatment can prevent hospitalization in individuals with early COVID-19. Design, setting and participants: A randomized, double-blind, placebo-controlled study was conducted in non-hospitalized individuals with COVID-19 i…
International Journal of Infectious Diseases
24.06.2021
We read the research article “A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness” by Ahmed S et al published with great interest. In this article, they have described the results of the randomized clinical trial conducted for the efficacy of ivermectin given in COVID-19 patients. (Ahmed S et al 2021)
Clinical Infectious Diseases
14.06.2021
AbstractBackgroundDue to spatial heterogeneity in onchocerciasis transmission, the duration of ivermectin mass drug administration (MDA) required for eliminating onchocerciasis will vary within endemic areas and the occurrence of transmission “hotspots” is inevitable. The geographical scale at which stop-MDA decisions are made will be a key driver in how rapidly national programs can scale down active intervention upon achieving the epidemiological targets for elimination.MethodsWe used 2 onchocerciasis…
Journal of Medical Virology
7.06.2021
Journal of Medical Virology, EarlyView.
American Journal of Tropical Medicine and Hygiene
2.06.2021
Journal Name: The American Journal of Tropical Medicine and HygieneVolume: 104Issue: 6Pages: 2165-2168
BMC Infectious Diseases
4.05.2021
Abstract Background and objectives An effective treatment option is not yet available for SARS-CoV2, which causes the COVID-19 pandemic and whose effects are felt more and more every day. Ivermectin is among the drugs whose effectiveness in treatment has been investigated. In this study; it was aimed to investigate the presence of gene mutations that alter ivermectin metabolism and cause toxic effects in patients with severe COVID-19 pneumonia…
Malaria Journal
26.04.2021
…f MDA on disease control and elimination. This study aimed to identify limitations and enabling factors impacting involvement at different stages of a large cluster-randomized trial assessing the effect of combining dihydroartemisinin-piperaquine (DP) and ivermectin (IVM) in malaria transmission in The Gambia. Methods This social science study used a mixed-methods approach. Qualitative data were collected in intervention …
Journal of the American Medical Association
13.04.2021
This randomized trial compares the effects of ivermectin vs placebo on time to symptom resolution within 21 days among patients with mild COVID-19.
Lancet Infectious Diseases
31.03.2021
…coralis infection has long been neglected by the scientific community, despite the threat it poses to the individual and collective health.1 In 2020, WHO included this infection in its public health targets for 2030,2 pointing out that control measures for strongyloidiasis are of paramount importance in endemic countries. This target might necessitate the massive use of ivermectin, the only drug, effective in a single dose, that can contribute to decisively decreasing the prevalence of this deadly parasite.
International Journal of Infectious Diseases
14.07.2021
…atment options include 1) RNA-dependent RNA polymerase inhibitors (e.g., remdesivir), 2) protease inhibitors (e.g., lopinavir/ritonavir), 3) blockade of virus-cell membrane fusion with a recombinant human angiotensin-converting enzyme (e.g., ivermectin), and 4) the modulation of the human immune system (e.g., interleukin-6 blockers), 5) Janus kinase inhibitor (e.g., ruxitinib), 6) anti-tumour necrosis factor, 7) convalescent plasma, and finally 8) corticosteroids (Hossen et al., 2020; Sanders et al., 2020).
Infection
6.07.2021
…e (WHO scale 5–6). Treatment with nMABs may be considered for selected inpatients with an early SARS-CoV-2 infection that are not hospitalized for COVID-19. Convalescent plasma, azithromycin, ivermectin or vitamin D3 should not be used in COVID-19 routine care. Conclusion For COVID-19 drug therapy, there are several options that are sufficiently supported by evidence. The living guidance will be updated as new evidence emerges.
BMC Infectious Diseases
2.07.2021
…ntific community has been investigating re-purposed treatments to prevent disease progression in coronavirus disease (COVID-19) patients. Objective To determine whether ivermectin treatment can prevent hospitalization in individuals with early COVID-19. Design, setting and participants: A randomized, double-blind, placebo-controlled study was conducted in non-hospitalized individuals with COVID-19 i…
International Journal of Infectious Diseases
24.06.2021
We read the research article “A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness” by Ahmed S et al published with great interest. In this article, they have described the results of the randomized clinical trial conducted for the efficacy of ivermectin given in COVID-19 patients. (Ahmed S et al 2021)
Clinical Infectious Diseases
14.06.2021
AbstractBackgroundDue to spatial heterogeneity in onchocerciasis transmission, the duration of ivermectin mass drug administration (MDA) required for eliminating onchocerciasis will vary within endemic areas and the occurrence of transmission “hotspots” is inevitable. The geographical scale at which stop-MDA decisions are made will be a key driver in how rapidly national programs can scale down active intervention upon achieving the epidemiological targets for elimination.MethodsWe used 2 onchocerciasis…
Lancet Infectious Diseases
9.06.2021
During the second wave of the COVID-19 pandemic in India, which began in March, 2021, demand on the health-care system has far exceeded capacity. Despite crippling shortages, patients are prescribed a battery of ineffective therapeutic interventions.1 Ivermectin, hydroxychloroquine, and herbal cocktails continue to receive state patronage.2,3,4 On May 8, 2021, 2-deoxy-D-glucose was given emergency authorisation, stating that it will “save precious lives” without any published evidence that it impacts mo…
Infection
1.06.2021
…hil count. Stool examination confirmed the presence of S. stercoralis larvae. The patient was treated with a 4-day course of Ivermectin with full recovery. Discussion We report the first case of S. stercoralis infection following an 11-day treatment with high-dose steroids and Tocilizumab for severe COVID-19. Clinicians should be aware of the risk of strongyloidiasis as a complication of the treatment for severe COVID-19.
BMC Infectious Diseases
4.05.2021
Abstract Background and objectives An effective treatment option is not yet available for SARS-CoV2, which causes the COVID-19 pandemic and whose effects are felt more and more every day. Ivermectin is among the drugs whose effectiveness in treatment has been investigated. In this study; it was aimed to investigate the presence of gene mutations that alter ivermectin metabolism and cause toxic effects in patients with severe COVID-19 pneumonia…

Aktuelle smitsomme sygdomme [3]

Medscape Infectious Diseases
14.07.2021
A meta-analysis of randomized trials of ivermectin suggests protection against COVID-19, but could there be problems with the study? Dr F. Perry Wilson digs in.
Medscape Infectious Diseases
6.05.2021
The daughter of a 68-year-old woman, who has been in an Illinois ICU for a month, sued to get the controversial drug the FDA has warned against administered to her mom. A judge granted the family's wish.
Medscape Infectious Diseases
14.07.2021
A meta-analysis of randomized trials of ivermectin suggests protection against COVID-19, but could there be problems with the study? Dr F. Perry Wilson digs in.

Nyhedsbrev

Skriv din email adresse og modtag nyheder om hjemmesiden.


© 2021 Dansk Selskab for Infektionsmedicin

version: 2.9.0 ● design: C P Fischer

Side indlæst på 0,757 s

Cookies og privatliv